Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting

Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of a Trials in Progress poster for its Phase I/II clinical trial of BT7480 at the 2022 ASCO Annual Meeting in Chicago, IL, scheduled for June 5, 2022. BT7480 is a novel Bicycle TICA™ targeting Nectin-4 while agonizing CD137 in patients with advanced malignancies. The study aims to evaluate the therapeutic potential of BT7480 in addressing unmet medical needs in oncology. Additional details about the study will be available on their website following the presentation.

Positive

• Presentation of BT7480 at ASCO Annual Meeting could boost visibility among investors and the medical community.
• Phase I/II trial indicates progress toward advanced clinical development for BT7480.

Negative

• None.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present a Trials in Progress poster highlighting the Phase I/II clinical trial of BT7480, a novel, fully synthetic Bicycle TICA^™ targeting Nectin-4 and agonizing CD137, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 3-7, 2022.

Poster Presentation Details

Title: A Combined Phase I/II Study of a Novel Bicycle Tumor-targeted Immune Cell Agonist® BT7480 in Patients with Nectin-4 Associated Advanced Malignancies
Abstract #: TPS2689
Poster #: 332b
Presenter: Kyriakos P. Papadopoulos, START San Antonio
Session Title: Development Therapeutics – Immunotherapy
Date/Time: Sunday, June 5, 2022 at 9:00 a.m. ET

The poster will be available on the Publications section of bicycletherapeutics.com following the presentation.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts. For more information, visit bicycletherapeutics.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s anticipated participation in the ASCO Annual Meeting. Bicycle may not actually achieve the intentions disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the intentions disclosed in these forward-looking statements as a result of various factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, and which are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 5, 2022, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005544/en/

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com

617 203-8300



Media:

Argot Partners

Sarah Sutton

bicycle@argotpartners.com

212-600-1902

Source: Bicycle Therapeutics plc

FAQ

What is the focus of Bicycle Therapeutics' clinical trial for BT7480?

The trial focuses on evaluating BT7480, targeting Nectin-4 and agonizing CD137 in patients with advanced malignancies.

When and where will the ASCO Annual Meeting take place?

The ASCO Annual Meeting will take place from June 3-7, 2022, in Chicago, IL.

What is the significance of the Trials in Progress poster presentation?

The poster presentation aims to provide updates on the Phase I/II clinical trial, showcasing the company's efforts to develop innovative treatments in oncology.

What are the future implications of BT7480's trial results?

The trial results will inform the potential effectiveness and safety of BT7480, impacting its development and possible market entry.

How can investors access the poster presentation details?

Details of the poster presentation will be made available on Bicycle Therapeutics' website following the event.